Today: 22 July 2026
Qantas share price slides on Iran conflict and oil spike — what investors watch next
2 March 2026
1 min read

Qantas share price slides on Iran conflict and oil spike — what investors watch next

Sydney, March 2, 2026, 18:00 (AEDT) — After-hours

  • Qantas dropped roughly 5.4% to close at A$9.41, swinging from A$8.92 to A$9.50 during the session.
  • Brent crude surged nearly 13% at the open in Asia before settling around a 7% gain.
  • Qantas shares will go ex-dividend on March 10, ahead of the interim payout slated for April 15.

Shares of Qantas Airways Ltd lost ground Monday, caught up in a sector-wide selloff as concerns over escalating tensions between the U.S. and Iran sparked worries about rising fuel costs and potential travel disruptions. Latest price: A$9.41.

Shares in Cathay Pacific, Singapore Airlines and Japan Airlines each slid over 5% as investors reassessed airline stocks in the region, according to Reuters. Morningstar’s Nicole Lim pointed to worries over rising fuel prices, flight cancellations, and the extra expense of rerouting flights with airports and airspace closed.

This hits Qantas, too, despite not flying straight to the Middle East. Once major hubs are knocked offline, connections unravel—airlines might burn extra fuel on stretched-out routes or end up with half-empty flights just to reposition crews and jets.

Oil’s the hammer in play right now. Brent crude surged roughly 10%, trading at about $80 a barrel over the counter on Sunday. Analysts flagged a possible spike to $100 if trouble near the Strait of Hormuz sticks around. “The key factor here is the closing of the Strait of Hormuz,” said Ajay Parmar, director of energy and refining at ICIS. Reuters

Chaos at major airports was clear. According to Reuters, Dubai, Abu Dhabi and Doha either shut down or faced heavy restrictions, with regional airspace closures leaving passengers stuck and airlines scrambling to cancel or reroute flights. “It’s the sheer volume of people and the complexity,” said UK-based aviation analyst John Strickland. Reuters

Australian shares barely flinched. The S&P/ASX 200 edged up 0.03% by the close, lifted by energy and gold stocks. Travel names struggled.

Qantas shares reflected the jitters—no fresh company news drove the move. The stock dropped as low as A$8.92 before bouncing back, traders wrestling with the question of pricey fuel’s duration and the extent of global schedule fallout.

The calendar throws in a fresh wrinkle. Qantas goes ex-dividend March 10, so anyone buying after that date misses out on the next payout. That timing can shake up positioning, particularly with markets this jumpy.

The risk on the downside is clear enough: persistent high crude and ongoing Gulf hub bottlenecks could double up the pain for the sector — with rising costs plus weaker demand — and that’s true even for carriers steering clear of those routes. Quick de-escalation, though, would probably claw back part of Monday’s panic move.

Crude prices and the latest conflict headlines are likely to draw traders’ focus heading into Tuesday. For Qantas, the calendar circles March 10—the ex-dividend date for the stock.

Michał Rogucki is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic developments. A graduate of Humboldt University of Berlin, he previously worked in investment research and market analysis before transitioning to financial journalism. He covers the trends and events that matter most to investors worldwide.

Stock Market Today

  • Pro Medicus Trades at 233% Above Estimated Fair Value, Analysts Caution on Premium
    July 21, 2026, 10:36 PM EDT. Pro Medicus (ASX: PME) is currently priced at a 233% premium above its fair value estimate as of July 22. The company has achieved notable success with US academic hospital contracts, primarily through its Visage 7 offering and continued R&D spending in Berlin and New York. While all major public tenders in 2021-6 out of 6-were secured, expansion in US midmarket hospitals continues to lag. Analysts maintain a fair value of $54 per share and project a 15% compound annual growth rate in revenue over five years.
Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears
Previous Story

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom
Next Story

Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom

Go toTop